Rallybio Corp is a clinical-stage biotechnology company dedicated to the development of innovative therapies for rare diseases, primarily within the realms of immunology and hematology. The company has established a promising pipeline of biologic drug candidates progressing through clinical trials, supported by a highly experienced management team with extensive industry expertise. Through strategic partnerships, Rallybio amplifies its potential to deliver transformative treatments in underserved therapeutic areas, reflecting its commitment to enhancing patient outcomes. With a targeted focus…